Metreleptin for treating lipodystrophy – Final Appraisal Determination

In DRAFT guidance metreleptin is recommended for leptin deficiency in generalised lipodystrophy in those ≥2 yrs, and in partial lipodystrophy in those ≥12 yrs with inadequate metabolic control despite standard treatments (HbA1c >7.5% and/or fasting triglycerides 5.0 mmol/L).

Source:

National Institute for Health and Care Excellence